Cytovance Biologics, an important US-based contract development and manufacturing organization (CDMO) helping the pharmaceutical organization, announced the expansion of its upstream process advancement with the addition of perfusion capabilities.
The novel ability offers pharmaceutical organizations with an additional process development option alongside traditional fed-batch production, allowing Cytovance to improve support programs that need higher productivity, increasing cell culture durations, and improving process flexibility while advancing biologics.
"Our goal is to continue expanding the technologies and expertise available to clients as the industry evolves," said Fuad Haddadin, Ph.D., Head of Research & Development at Cytovance Biologics. "By integrating perfusion into our development platform, we're giving sponsors greater flexibility while positioning Cytovance to support the future of biologics manufacturing."
Unlike outdated fed-batch processes, perfusion incessantly replenishes fresh media while eliminating spent media, enabling cell cultures to remain healthy and creative for significantly longer periods. The strategies enhanced productivity, maintained more consistent culture circumstances, and lessened the accumulation of metabolic byproducts, which may affect product quality.
According to Towards Healthcare, the Biologics CDMO for mAb market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 23.11 billion in 2026 to approximately USD 58.64 billion by 2035, representing a compound annual growth rate (CAGR) of 10.9% from 2026 to 2035, driven by collaboration with a biologics CDMO confirms that every stage of the biomanufacturing process is enhanced for effectiveness, quality, and scalability, eventually authorizing the advancement of life-changing medication. As production of biologics becomes more challenging and data-driven, digital twins offer a significant tool for innovation and effectiveness. They are renovating the landscape of biologics production by offering a virtual replica of physical processes, tools, or whole production facilities. They enable manufacturers to predict the results of process changes without disrupting actual processes by simulating production conditions. As a foremost CDMO for mAb production, Syngene provides end-to-end biologics advancement and manufacturing services for mammalian and microbial technology.
The addition of perfusion capabilities allows Cytovance to help clients evaluate various upstream manufacturing approaches for monoclonal antibodies, recombinant proteins, and different biologic modalities, specifically during early process development.
"Perfusion is not intended to replace fed-batch manufacturing; it's another tool that allows us to develop the right process for each client's program," said Charles Oluremi Solanke, Senior Scientist, Upstream Process Development at Cytovance Biologics. "By expanding our expertise in both approaches, we're able to help companies optimize productivity, improve process consistency, and prepare programs for long-term manufacturing success."
This modern spending builds on Cytovance's new expansion of in-house cell line advancement and formulation development solutions, further establishing its integrated CDMO providing and simplifying the advancement journey for pharmaceutical innovators.
Cytovance Biologics is an established large molecule CDMO that is large enough to support at each stage and small enough to stay agile, offering programs with the care it deserves. For 20 years, Team Cytovance has provided flexibility and ingenuity in a full range of combined services, supportive mammalian- and microbial-derived products on their journey from molecule to commercial production.
A recent report by Towards Healthcare highlights that the biologics CDMO for mAb market is witnessing growth because outsourcing with a biologics CDMO enables pharmaceutical organizations to access the equipment and facilities they require, without needing the capital spending to purchase or build them. This also offers the companies increased flexibility should a required change occur in the future. Biologics CDMO organization to be backed by private equity, giving them the money needed to upgrade equipment and stay on the cutting-edge of development and production technology. Biologics CDMOs support pharmaceutical companies to scale more smartly by lowering their challenges. An outsourced manufacturer is able to support meeting manufacturing deadlines and amplified demand by shifting production volume as required, flawlessly adding a drug variation, and scaling production without the extra expenses of labor and ability space.
